Abstract
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have